Key result
GP IIb/IIIa receptor antagonists impact the activated clotting time of heparinized blood during percutaneous transluminal procedures.
Answers are grounded in this paper and cite their sources.
Examines the effects of GP IIb/IIIa receptor antagonists on activated clotting time in heparinized patients, highlighting the interaction between antiplatelet therapy and heparin monitoring.
The activated clotting time (ACT) is a functional measure of the intrinsic coagulation pathway that has become a standard monitoring device of heparin. In the Evaluation of c7E3 Fab in the Prevention of Ischemic Complications (EPIC) study, ACT has been measured during percutaneous transluminal
No takes yet. Share an insight, caveat, or question.
Himber et al. (2000) studied this question. GP IIb/IIIa receptor antagonists impact the activated clotting time of heparinized blood during percutaneous transluminal procedures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: